Harnessing immune responses in the tumor microenvironment: all signals needed
An agonist CD40 monoclonal antibody (CP-870,893), in combination with gemcitabine, is
well tolerated in patients with advanced pancreatic adenocarcinoma. The combination
results in induction of cytokines, B cell activation, and clinical responses. These findings
support testing of immunotherapies in combination with other established and targeted
therapies. Clin Cancer Res; 19 (22); 6061–3.© 2013 AACR.
well tolerated in patients with advanced pancreatic adenocarcinoma. The combination
results in induction of cytokines, B cell activation, and clinical responses. These findings
support testing of immunotherapies in combination with other established and targeted
therapies. Clin Cancer Res; 19 (22); 6061–3.© 2013 AACR.
Abstract
An agonist CD40 monoclonal antibody (CP-870,893), in combination with gemcitabine, is well tolerated in patients with advanced pancreatic adenocarcinoma. The combination results in induction of cytokines, B cell activation, and clinical responses. These findings support testing of immunotherapies in combination with other established and targeted therapies. Clin Cancer Res; 19(22); 6061–3. ©2013 AACR.
AACR